Shrimp-Derived nanoparticles take on denture fungus
NCT ID NCT07694024
First seen Jul 09, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This study compares a new 1% nanochitosan solution to standard nystatin oral suspension for treating Newton's type II denture stomatitis, a fungal infection causing redness and inflammation under dentures. The trial enrolls 30 complete denture wearers diagnosed by an oral specialist. Researchers measure how well each treatment reduces lesion size, burning sensation, and fungal count, aiming to find a safer, natural alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 1% nanochitosan solution
- What this could lead to
- If effective, nanochitosan could offer a natural, biocompatible alternative to standard antifungal drugs for treating denture-related mouth inflammation.
- What could go wrong
- This is a small Phase 2 trial with only 30 participants, so results may not apply broadly. Nanochitosan is still experimental and may not work as well as nystatin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC ATROPHIC CANDIDIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Dentistry, Kerman University of Medical Sciences
Kerman, Kerman, 7618868345, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.